Role of Cerebrospinal Fluid Biomarkers and (18)F-florbetapir PET Imaging in the Diagnosis of Primary Progressive Aphasia: A Retrospective Analysis

Giulia Perini, Matteo Cotta Ramusino, Elena Sinforiani, Diego Franciotta, Giusppe Trifirò, Mauro Ceroni, Alfredo Costa

Research output: Contribution to journalArticle

Abstract

The use of biomarkers has recently supported the association between Alzheimer's disease (AD) pathology and the logopenic variant of primary progressive aphasia (PPA). We aim to investigate possible differences in cerebrospinal fluid (CSF) biomarker concentrations in the three PPA variants, and to assess any agreement between CSF biomarkers and (18)F-florbetapir PET. A group of 10 PPA were retrospectively enrolled. Patients with logopenic variant (lvPPA) showed different levels of Aβ1-42 and p-tau compared to nonfluent/agrammatic and semantic variants (nfv/svPPA). All nfv/svPPA patients had negative amyloid PET. Among the lvPPA group, a negative amyloid PET was found only in one patient, who was also the only one to display a normal CSF. Thus, this small cohort appeared to display an excellent agreement between CSF and (18)F-florbetapir PET and suggest that these examinations may have the same validity in detecting in vivo evidence of AD pathology in PPA clinical variants.

Original languageEnglish
Pages (from-to)282-284
Number of pages3
JournalAlzheimer Disease and Associated Disorders
Volume33
Issue number(3)
Early online dateJan 10 2019
DOIs
Publication statusPublished - 2019

Fingerprint

Primary Progressive Aphasia
Cerebrospinal Fluid
Biomarkers
Amyloid
Alzheimer Disease
Pathology
Semantics
florbetapir

Cite this

@article{7fefe7cae0ac4d7fac5bdc0a9febe4cf,
title = "Role of Cerebrospinal Fluid Biomarkers and (18)F-florbetapir PET Imaging in the Diagnosis of Primary Progressive Aphasia: A Retrospective Analysis",
abstract = "The use of biomarkers has recently supported the association between Alzheimer's disease (AD) pathology and the logopenic variant of primary progressive aphasia (PPA). We aim to investigate possible differences in cerebrospinal fluid (CSF) biomarker concentrations in the three PPA variants, and to assess any agreement between CSF biomarkers and (18)F-florbetapir PET. A group of 10 PPA were retrospectively enrolled. Patients with logopenic variant (lvPPA) showed different levels of Aβ1-42 and p-tau compared to nonfluent/agrammatic and semantic variants (nfv/svPPA). All nfv/svPPA patients had negative amyloid PET. Among the lvPPA group, a negative amyloid PET was found only in one patient, who was also the only one to display a normal CSF. Thus, this small cohort appeared to display an excellent agreement between CSF and (18)F-florbetapir PET and suggest that these examinations may have the same validity in detecting in vivo evidence of AD pathology in PPA clinical variants.",
author = "Giulia Perini and {Cotta Ramusino}, Matteo and Elena Sinforiani and Diego Franciotta and Giusppe Trifir{\`o} and Mauro Ceroni and Alfredo Costa",
year = "2019",
doi = "10.1097/WAD.0000000000000289",
language = "English",
volume = "33",
pages = "282--284",
journal = "Alzheimer Disease and Associated Disorders",
issn = "0893-0341",
publisher = "Lippincott Williams and Wilkins",
number = "(3)",

}

TY - JOUR

T1 - Role of Cerebrospinal Fluid Biomarkers and (18)F-florbetapir PET Imaging in the Diagnosis of Primary Progressive Aphasia

T2 - A Retrospective Analysis

AU - Perini, Giulia

AU - Cotta Ramusino, Matteo

AU - Sinforiani, Elena

AU - Franciotta, Diego

AU - Trifirò, Giusppe

AU - Ceroni, Mauro

AU - Costa, Alfredo

PY - 2019

Y1 - 2019

N2 - The use of biomarkers has recently supported the association between Alzheimer's disease (AD) pathology and the logopenic variant of primary progressive aphasia (PPA). We aim to investigate possible differences in cerebrospinal fluid (CSF) biomarker concentrations in the three PPA variants, and to assess any agreement between CSF biomarkers and (18)F-florbetapir PET. A group of 10 PPA were retrospectively enrolled. Patients with logopenic variant (lvPPA) showed different levels of Aβ1-42 and p-tau compared to nonfluent/agrammatic and semantic variants (nfv/svPPA). All nfv/svPPA patients had negative amyloid PET. Among the lvPPA group, a negative amyloid PET was found only in one patient, who was also the only one to display a normal CSF. Thus, this small cohort appeared to display an excellent agreement between CSF and (18)F-florbetapir PET and suggest that these examinations may have the same validity in detecting in vivo evidence of AD pathology in PPA clinical variants.

AB - The use of biomarkers has recently supported the association between Alzheimer's disease (AD) pathology and the logopenic variant of primary progressive aphasia (PPA). We aim to investigate possible differences in cerebrospinal fluid (CSF) biomarker concentrations in the three PPA variants, and to assess any agreement between CSF biomarkers and (18)F-florbetapir PET. A group of 10 PPA were retrospectively enrolled. Patients with logopenic variant (lvPPA) showed different levels of Aβ1-42 and p-tau compared to nonfluent/agrammatic and semantic variants (nfv/svPPA). All nfv/svPPA patients had negative amyloid PET. Among the lvPPA group, a negative amyloid PET was found only in one patient, who was also the only one to display a normal CSF. Thus, this small cohort appeared to display an excellent agreement between CSF and (18)F-florbetapir PET and suggest that these examinations may have the same validity in detecting in vivo evidence of AD pathology in PPA clinical variants.

U2 - 10.1097/WAD.0000000000000289

DO - 10.1097/WAD.0000000000000289

M3 - Article

C2 - 30640253

VL - 33

SP - 282

EP - 284

JO - Alzheimer Disease and Associated Disorders

JF - Alzheimer Disease and Associated Disorders

SN - 0893-0341

IS - (3)

ER -